IN2015DN04209A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN04209A IN2015DN04209A IN4209DEN2015A IN2015DN04209A IN 2015DN04209 A IN2015DN04209 A IN 2015DN04209A IN 4209DEN2015 A IN4209DEN2015 A IN 4209DEN2015A IN 2015DN04209 A IN2015DN04209 A IN 2015DN04209A
- Authority
- IN
- India
- Prior art keywords
- methods
- igf1r
- cancers
- insulin
- constituent
- Prior art date
Links
- 102000004584 Somatomedin Receptors Human genes 0.000 abstract 3
- 108010017622 Somatomedin Receptors Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091028056 Mir-7 microRNA precursor Proteins 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012904570A AU2012904570A0 (en) | 2012-10-18 | Cancer therapy using miRNAs | |
| PCT/AU2013/001208 WO2014059484A1 (en) | 2012-10-18 | 2013-10-18 | CANCER THERAPY USING miRNAs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN04209A true IN2015DN04209A (enrdf_load_stackoverflow) | 2015-10-16 |
Family
ID=50487345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4209DEN2015 IN2015DN04209A (enrdf_load_stackoverflow) | 2012-10-18 | 2013-10-18 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9795626B2 (enrdf_load_stackoverflow) |
| EP (1) | EP2908830A4 (enrdf_load_stackoverflow) |
| CN (1) | CN104994861B (enrdf_load_stackoverflow) |
| IN (1) | IN2015DN04209A (enrdf_load_stackoverflow) |
| WO (1) | WO2014059484A1 (enrdf_load_stackoverflow) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3800256A1 (en) * | 2012-11-06 | 2021-04-07 | InteRNA Technologies B.V. | Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway |
| ES2596711B1 (es) * | 2015-07-09 | 2017-10-27 | Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Paz | Determinación de la metilación y niveles de un miARN en respuesta a un compuesto antitumoral basado en platino |
| CN106367419A (zh) * | 2016-10-10 | 2017-02-01 | 徐州医科大学 | 具有神经保护作用的反义寡核苷酸、药物组合物及其应用 |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3066350A1 (en) * | 2017-06-06 | 2018-12-13 | The Johns Hopkins University | Induction of synthetic lethality with epigenetic therapy |
| CN111183235A (zh) * | 2017-10-03 | 2020-05-19 | 基因序列有限公司 | 使用微rna基因表达来对黑素瘤进行诊断、分期和监测的方法 |
| CN109536497A (zh) * | 2018-11-28 | 2019-03-29 | 同济大学 | 日本血吸虫感染及其组分在人类肿瘤预防和治疗中的应用 |
| US12058196B1 (en) | 2020-03-26 | 2024-08-06 | Amazon Technologies, Inc. | Data transfer timeout management |
| US11750706B1 (en) * | 2020-03-26 | 2023-09-05 | Amazon Technologies, Inc. | Data transmission time management |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2633754C (en) * | 2006-01-05 | 2013-06-18 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
| CA2781571A1 (en) | 2009-11-24 | 2011-06-03 | The University Of Western Australia | Modulation of epidermal growth factor receptor ligands |
-
2013
- 2013-10-18 WO PCT/AU2013/001208 patent/WO2014059484A1/en active Application Filing
- 2013-10-18 US US14/436,638 patent/US9795626B2/en active Active
- 2013-10-18 EP EP13847499.4A patent/EP2908830A4/en not_active Withdrawn
- 2013-10-18 CN CN201380065503.0A patent/CN104994861B/zh not_active Expired - Fee Related
- 2013-10-18 IN IN4209DEN2015 patent/IN2015DN04209A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104994861B (zh) | 2019-10-11 |
| WO2014059484A1 (en) | 2014-04-24 |
| CN104994861A (zh) | 2015-10-21 |
| EP2908830A1 (en) | 2015-08-26 |
| US9795626B2 (en) | 2017-10-24 |
| EP2908830A4 (en) | 2016-11-30 |
| US20150366895A1 (en) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN04209A (enrdf_load_stackoverflow) | ||
| PH12015501738A1 (en) | Androgen receptor modulators and uses thereof | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| PH12015500825B1 (en) | Substituted benzene compounds | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12013500481A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12012502419A1 (en) | Estrogen receptor modulators and uses thereof | |
| MX2013011922A (es) | Compuestos de benceno substituido. | |
| PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| GB201106750D0 (en) | Novel compounds | |
| IN2015DN02032A (enrdf_load_stackoverflow) | ||
| IN2014DN07414A (enrdf_load_stackoverflow) | ||
| MX2015007180A (es) | Moduladores del receptor huerfano gamma relacionado con retinoide (ror-gamma) para usarse en el tratamiento de enfermedades autoinmunes inflamatorias. | |
| MY185016A (en) | Progenitor cells of mesodermal lineage | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| IN2015MN00027A (enrdf_load_stackoverflow) | ||
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX361349B (es) | Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas. | |
| MX2014010713A (es) | Activacion de procaspasa 3 mediante terapia de combinacion. | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
| PH12012501548A1 (en) | Compositions comprising sugar-cysteine products | |
| MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
| MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
| MX2013008559A (es) | Derivados de leptina. |